Wet Macular Degeneration: Symptoms, Treatment and Living Well
Understanding Wet Macular Degeneration
Wet macular degeneration, also known as wet age-related macular degeneration (wet AMD), is a serious eye condition that can cause rapid, significant changes to your central vision. Although it accounts for only about 10 to 15 percent of all AMD cases, wet AMD is responsible for the majority of severe vision loss associated with the disease. According to a 2024 review published in JAMA, age-related macular degeneration affects approximately 20 million people in the United States, and wet AMD accounts for roughly 90% of AMD-related cases of severe vision loss (JAMA, 2024). At Greenwich Ophthalmology Associates, our fellowship-trained retina specialists in the greater NY/CT region provide advanced diagnostic imaging and personalized treatment plans to help preserve your sight.
The macula is a small but critical area at the center of the retina responsible for the sharp, detailed vision you rely on for reading, driving, and recognizing faces. It contains a dense concentration of light-sensitive cells called photoreceptors that convert light into the electrical signals your brain interprets as images. When the macula is healthy, your central vision is clear and precise.
Wet AMD occurs when abnormal blood vessels grow beneath the retina in a process called choroidal neovascularization (CNV). These fragile new vessels leak blood and fluid into the macula, causing it to swell and damaging the surrounding tissue. Without treatment, this leakage can create scar tissue that permanently replaces healthy retinal cells, leading to irreversible central vision loss.
Wet AMD most commonly affects adults over age 50, and the risk increases with each decade of life. Additional factors include a family history of macular degeneration, smoking, cardiovascular disease, and being of European descent. You can learn more about these influences on our page about AMD risk factors.
Symptoms of Wet AMD
The symptoms of wet macular degeneration often develop quickly and can progress over days to weeks if left untreated. One of the earliest and most recognizable signs is metamorphopsia, a visual distortion that makes straight lines appear bent, wavy, or crooked. You may first notice this when looking at door frames, window blinds, or lines of text. This distortion occurs because fluid leaking from abnormal blood vessels displaces the photoreceptor cells in the macula.
As fluid accumulates under or within the macula, you may notice a blurred or hazy spot in the center of your visual field. This can make it difficult to read, watch television, or perform tasks that require fine detail. Some patients experience a scotoma, which is a dark or blank area in their central vision. This may start small and expand over time as more retinal tissue is damaged by leaking fluid and blood.
Wet AMD can affect how colors appear, making them look faded, washed out, or less vivid than usual. This occurs because the cone cells in the macula, which are responsible for color vision, become compromised by swelling and fluid accumulation. You may also find it harder to see in dim environments or notice that you need brighter lighting for reading and close-up tasks.
How Wet AMD Differs from Dry AMD
While both forms of age-related macular degeneration affect the macula, they differ in their underlying mechanisms and treatment approaches. Dry macular degeneration is characterized by the gradual buildup of drusen, which are small yellow deposits of lipid and protein beneath the retina. Over time, these deposits can thin and break down the macula's supporting tissue, leading to slow, progressive vision changes. Most people with AMD begin with the dry form.
Wet AMD is distinguished by the development of new, abnormal blood vessels growing from the choroid layer beneath the retina into the macular area. These vessels are structurally weak and prone to leaking fluid and blood, which causes the more rapid and severe vision loss compared to the dry form. This key difference is also what makes wet AMD treatable with targeted anti-VEGF injection therapy.
Dry AMD can remain stable for years or progress through early, intermediate, and advanced stages. In some patients, dry AMD converts to wet AMD when the retina signals for new blood vessel growth in response to reduced oxygen supply. This conversion can happen at any stage, which is why regular monitoring with dilated exams, retinal imaging, and at-home Amsler grid testing is essential even when the dry form appears mild.
What Causes Wet Macular Degeneration
The development of wet AMD involves a combination of aging, genetic predisposition, and environmental factors that trigger abnormal blood vessel growth beneath the retina. Vascular endothelial growth factor (VEGF) is a protein that signals the body to form new blood vessels. In wet AMD, the retina produces excess VEGF, which stimulates the growth of fragile, leaky vessels beneath the macula. This overproduction of VEGF is the primary target of current wet AMD treatments.
Research has identified several genes that influence AMD risk, including the complement factor H (CFH) and ARMS2/HTRA1 genes. Having a close family member with AMD significantly increases your likelihood of developing the disease. Genetic factors may explain why some patients with dry AMD convert to wet AMD while others do not.
Smoking is the strongest modifiable risk factor for developing wet AMD, roughly doubling or tripling the risk compared to nonsmokers. High blood pressure, obesity, and prolonged ultraviolet light exposure also contribute to disease development. Making positive lifestyle changes, including following a nutrient-rich diet for macular health, can help reduce your overall risk and support long-term retinal health.
Frequently Asked Questions
Anti-VEGF injections are the primary treatment for wet AMD. Medications such as ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo) are injected directly into the eye to block the VEGF protein that drives abnormal blood vessel growth. By reducing VEGF activity, the injections help stop leaking, reduce macular swelling, and in many cases stabilize or improve vision.
Treatment typically begins with a loading phase of monthly injections for the first three months. After that, our retina specialists use a treat-and-extend approach, gradually increasing the interval between injections based on how your eye responds. Many patients eventually move to injections every 8 to 16 weeks, though treatment schedules vary depending on individual disease activity.
Wet AMD affects central vision but does not typically cause total blindness. Even in advanced cases, peripheral vision usually remains intact, allowing you to navigate your surroundings and maintain a degree of independence. However, without treatment, central vision loss can become severe enough to affect reading, driving, and face recognition.
Faricimab (Vabysmo) is a newer bispecific antibody that blocks both VEGF-A and angiopoietin-2, two pathways involved in abnormal vessel growth and vascular leakage. Clinical trials have shown it can extend the time between injections to up to 16 weeks for some patients. Researchers are also exploring port delivery systems, gene therapy approaches, and longer-acting injectable agents.
Our retina specialists may recommend using an Amsler grid, a tool with a pattern of straight lines and a central dot that helps you detect subtle vision changes between appointments. You hold the grid at reading distance, cover one eye, and check for any areas where lines appear wavy, missing, or distorted. Reporting any new changes promptly allows your care team to adjust treatment before significant damage occurs.
Low vision rehabilitation programs can teach you how to use magnifiers, adaptive lighting, and assistive technology to maintain your daily routines. Local and online support groups also connect you with other patients who understand the emotional and practical challenges of managing ongoing vision changes. Our team can provide referrals to appropriate resources based on your needs.
Protect Your Vision with Expert Retina Care
Living with wet macular degeneration requires a partnership between you and a skilled retina team committed to preserving your sight. Understanding the symptoms, causes, and available treatments is the first step toward protecting your vision for the years ahead. Whether you are newly diagnosed or managing ongoing treatment, early detection and consistent treatment are critical for maintaining functional vision.
At Greenwich Ophthalmology Associates, our retina specialists bring decades of experience in diagnosing, treating, and monitoring wet AMD using advanced imaging and the latest injection therapies available in the greater NY/CT region. From personalized treatment plans to ongoing support and guidance, we are here to guide you through every step of your care. Patients considering cataract surgery alongside AMD management can benefit from our coordinated approach to both conditions. Schedule a comprehensive retina evaluation to take an active role in protecting your vision.
What our Patients say
4.8
Reviews
(3,408)